课题基金 / 基金详情

Prevention of Brain Metastasis Relapse through Modulation of Age-related Gut Microbiota-Immune Cross talk

Prevention of Brain Metastasis Relapse through Modulation of Age-related Gut Microbiota-Immune Cross talk
通过调节与年龄相关的肠道微生物群-免疫串扰来预防脑转移复发
批准号:
10287850
负责人:
Siyuan Zhang
金额:
$21.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-03 至 2022-04-30

项目摘要

项目成果

Siyuan Zhang的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary Metastasis is the major cause of cancer mortality, with brain metastasis being the most aggressive and incurable form of metastatic recurrence. The prognosis for breast cancer patients with brain metastasis is devastatingly poor with a median survival of less than six months. Brain metastasis relapse depends on the intricate interplay between disseminated tumor cells and components of the brain metastatic microenvironment - the niche. To combat breast cancer mortality, it is imperative to develop rationally-designed strategies to prevent brain metastasis relapse. The immune system plays a significant role in regulating both primary and metastatic tumors. The gut microbiota - an ecological community of commensal, symbiotic, and pathogenic microorganisms consistently primes and reshapes the immune surveillance system during aging. Mounting evidence in the neuroscience field demonstrated a clear connection between gut microbiota dysbiosis and brain inflammation as well as various neurological diseases. As brain metastasis relapse often occurs in aged breast cancer survivors, in this proposed study, we will focus on delineating mechanisms by which the microbiota-host immune interaction influences metastatic progression in the aged female population. We postulate that age-related gut dysbiosis may reshape the brain immune metastatic niche to influence brain metastatic relapse. Our overarching goal is to dissect the mechanistic connection between gut dysbiosis and brain metastasis relapse and identify clinically actionable probiotics modulation strategies tailored to aged breast cancer survivors to prevent brain metastatic relapse. Based on well-established aging models, cutting-edge single-cell genomics, and metagenomics approaches, we will examine molecular changes in brain metastatic tumors with gut microbiota alterations in the aged host. Then design and test targeted microbiota-modulation strategies to prevent brain metastatic relapse in aged hosts. This project is the first attempt to explore the mechanistic link between the gut microbiota and breast cancer brain metastatic niche in the aging context. From the cancer prevention perspective, mechanistic insights via examining age-associated dysbiosis in regulating brain metastasis relapse will guide personalized microbiota-modulation strategy that is tailored to each breast cancer survivor to prevent deadly brain metastatic relapse.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neural Niche in Promoting Brain Metastatic Tumor Progression
  • 批准号:
    10675623
  • 项目类别:
  • 资助金额:
    $46.37万
  • 财政年份:
    2021
  • 负责人:
    Siyuan Zhang
  • 依托单位:
Prevention of Brain Metastasis Relapse through Modulation of Age-related Gut Microbiota-Immune Cross talk
  • 批准号:
    10613161
  • 项目类别:
  • 资助金额:
    $18.1万
  • 财政年份:
    2021
  • 负责人:
    Siyuan Zhang
  • 依托单位:
Neural Niche in Promoting Brain Metastatic Tumor Progression
  • 批准号:
    10298995
  • 项目类别:
  • 资助金额:
    $47.17万
  • 财政年份:
    2021
  • 负责人:
    Siyuan Zhang
  • 依托单位:
Neural Niche in Promoting Brain Metastatic Tumor Progression
  • 批准号:
    10636336
  • 项目类别:
  • 资助金额:
    $47.98万
  • 财政年份:
    2021
  • 负责人:
    Siyuan Zhang
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: